Abstract
Durability of Response with First-Line Combined Immune Checkpoint Inhibitor Therapy Compared to Checkpoint Inhibitor with VEGFR-TKI in Advanced Clear Cell Renal Cell Carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have